Valuation dashboard for ACADIA Pharmaceuticals Inc. (ACAD) with P/E 12.10, P/B 3.57, EV/EBITDA 37.93 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Analysis Summary
ACADIA Pharmaceuticals Inc. reported revenue of $1.07B in the most recent fiscal year, growing at a 5-year CAGR of 19.4%.
Trailing-twelve-month margins: gross margin 91.1%, operating margin 7.6%, net margin 33.4%.
At the current price of $27.54, ACAD trades at a P/E of 12.10 and an ROE of 32.39%. Market capitalisation stands at $4.7B.
Balance sheet quality for ACAD: current ratio of 3.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 12.10 |
| Price / Book | 3.57 |
| EV / EBITDA | 37.93 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-31.13 |
| vs Current Price | -213.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
| BLTE | Belite Bio, Inc | $6.8B | 8.75 | -10.1% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.7B | 6.71 | -34.1% | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | -410.2% | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.7B | 27.49 | 5.71 | |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.20 | -64.3% |
Price
| Price | $27.54 |
| Market Cap | $4.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 32.39% |
| Return on Invested Capital | 6.19% |
| Return on Assets | 21.83% |
| Gross Margin | 91.13% |
| Operating Margin | 7.59% |
| Net Margin | 33.42% |
Related companies: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks